VintaBio puts US$17M Philadelphia viral vector manufacturing facility up for sale
DSI Assignments has now opened the sale to potential buyers, offering both VintaBio’s intellectual property and its 22,500-square-foot production facility in Philadelphia, Pennsylvania.
USA—VintaBio has put its Philadelphia manufacturing facility and intellectual property up for sale following an October 27, 2026, transfer of its assets to an assignee as the company seeks to address its financial obligations through an insolvency process.
The company, which launched in 2023 as a contract development and manufacturing organisation (CDMO) specialising in viral vectors for cell and gene therapies, transferred its assets to DSI Assignments.
The process allows financially distressed businesses to sell assets and repay creditors under state law without pursuing federal bankruptcy proceedings.
DSI Assignments has now opened the sale to potential buyers, offering both VintaBio’s intellectual property and its 22,500-square-foot production facility in Philadelphia, Pennsylvania.
According to DSI, the facility represents a capital investment of $17 million and houses three manufacturing suites, fill-finish capabilities and supporting laboratories.
Facility and technology assets available
Opened in 2023 after VintaBio emerged from stealth, the facility was designed to support high-yield, high-purity production of adeno-associated virus serotype 8 (AAV8) vectors.
Its infrastructure also supports potential applications across other viral vector manufacturing platforms.
The intellectual property portfolio includes VintaCells, VintaProcess and the company’s extended-harvest methodologies.
These technologies, alongside the manufacturing infrastructure, could offer prospective buyers an opportunity to acquire established production capabilities and processes for developing cell and gene therapies.
Viral vector manufacturing faces capacity pressures
The sale comes as the viral vector manufacturing market continues to experience pressure from excess production capacity and weaker demand.
The sector attracted substantial investment as biotechnology companies sought reliable manufacturing partners to address supply constraints in the production of cell and gene therapies.
However, an August study by Intuition Labs found that market consolidation and capacity expansion have left viral vector manufacturing capacity exceeding clinical demand.
Although sponsors now have more manufacturing options, the study highlighted concerns about the financial stability of some CDMOs, creating uncertainty around long-term manufacturing partnerships.
Several companies have since scaled back or discontinued operations.
AmplifyBio shut down its operations in 2025, while Thermo Fisher Scientific closed its viral vector manufacturing facility in Lexington, Massachusetts, during the same year.
More recently, Charles River Laboratories closed its cell therapy CDMO facility in Hanover, Maryland, in February 2026.
The deadline for submitting bids for VintaBio’s assets is December 15, 2026, at 5 p.m. Eastern Time, according to DSI Assignments.
Be the first to leave a comment